患有的儿童 (6-16岁) 的饮食行为问题:一个横截面的比较研究
Özlem Kemer Aycan1, Hilal Aydin2, Özge Demircan Tulacı3
1Department of Pediatrics, Faculty of Medicine, Balıkesir University, Balıkesir, Turkiye.
Epilepsy & behavior : E&B
|March 15, 2026
概括
与健康同龄人相比,患有的儿童在饮食行为中没有显著差异. 然而,在群体中,在饮食行为中发现了性别差异,这需要进一步调查.
科学领域:
- 儿科神经学 儿科神经学
- 儿童精神病学 儿童精神病学
- 神经发育障碍 神经发育障碍
背景情况:
- 是一种常见的儿童和青少年神经系统疾病.
- 改变饮食行为是儿科的潜在问题.
- 了解这些行为对于全面的患者护理至关重要.
研究的目的:
- 评估患有的儿童和青少年的饮食行为障碍.
- 为了比较和非儿童之间的饮食行为.
- 为了确定对饮食行为的影响.
主要方法:
- 一项病例对照研究,涉及78名患有的儿童和62名健康对照 (6-16岁).
- 的诊断通过国际病联盟 (ILAE) 的标准得到证实.
- 儿童饮食行为调查问卷 (CEBQ) 的验证的土耳其版本给了这两个组.
主要成果:
- 患有的儿童和对照儿童之间的饮食行为得分没有统计学上显著的差异 (p > 0.05).
- 饮食行为与持续时间,发作类型或抗药物 (ASM) 使用没有显著的关联.
- 在群中观察到与性别相关的饮食行为差异 (p < 0.05).
结论:
- 根据CEBQ的评估,患者和健康对照儿童的饮食行为没有差异.
- 没有发现饮食行为与相关的临床特征之间的关联.
- 建议进行进一步的大规模研究,以探索儿科的性别特异性饮食行为模式.
相关概念视频
Epilepsy and Seizures: Overview
1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Binge Eating Disorders
691
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
691
Bulimia Nervosa
939
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
939
Antiepileptic Drugs: Glutamate Antagonists
1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Inborn Errors of Metabolism
986
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
986
Antiepileptic Drugs: Potassium Channel Activators
900
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
900


